P158 LONG-TERM SAFETY OF LANADELUMAB IN HEREDITARY ANGIOEDEMA (HAE): INTERIM RESULTS FROM THE HELP OLE STUDY

D. Johnston,A. Banerji, C. Nurse, P. Lu,E. Aygören-Pürsün,S. Kiani-Alikhan,D. Soteres,P. Lugar,B. Zuraw, R. Lockey, L. Schwartz

Annals of Allergy, Asthma & Immunology（2019）

引用 3|浏览5

暂无评分

摘要

Lanadelumab safety over 26 weeks at doses up to 300 mg every 2 weeks (Q2W) was evaluated in the HELP study. The long-term safety of lanadelumab is being assessed in the ongoing HELP open-label extension study (OLE; NCT02741596).

查看译文

关键词

hereditary angioedema,lanadelumab,long-term

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要